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18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of beneﬁt in the
management of aggressive B-cell non-Hodgkin’s lymphoma, such as diﬀuse large B-cell lymphoma and advanced stage follicular
lymphoma. The combination of anatomic and functional imaging aﬀo r d e db yF D G - P E T / C Th a sl e dt os u p e r i o rs e n s i t i v i t y
and speciﬁcity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when
compared to FDG-PET and CT alone. The use of FDG-PET/CT for posttreatment surveillance imaging remains controversial, and
further study is needed to ascertain whether this modality is cost eﬀective and appropriate for use in this setting.
1.Introduction
The lymphoproliferative disorders, which can be broadly
divided into Hodgkin’s (HL) and non-Hodgkin’s (NHL)
lymphoma, represent a heterogeneous group of lymphoid
malignancies that display varying patterns of biological
behavior and response to treatment [1]. It is estimated
that over 65,000 Americans will be diagnosed with NHL
with over 20,000 deaths in 2011, making it the eighth and
sixth most common cause of cancer death in men and
women, respectively [2]. The annual incidence of NHL is
trending upwards year on year; however, the overall 5-year
survival rate has been steadily improving due in part to
reﬁnements in treatment regimens which minimize patient
toxicity and maximize remission rates. Classiﬁcation of lym-
phomas according to the 2008 World Health Organization
classiﬁcation system groups lymphomas by cell type (i.e.,
the normal cell type that most resembles the tumor) and
deﬁnes phenotypic, molecular, or cytogenetic characteristics
with three major groupings, namely, the B-cell, T-cell, and
naturalkillercellneoplasms[3].Themostcommonsubtypes
of NHL aﬀecting adults are follicular lymphoma (FL) and
diﬀuse large B-cell lymphoma (DLBCL), which together
account for greater than 50% of NHL [4, 5]. Prognosis of
patients with NHL is aﬀected by the stage and grade of
disease as well as the histological subtype. Physicians often
classify NHL into indolent, aggressive, and highly aggressive
histologic subtypes for the purpose of estimating prognosis
and determining treatment options. This paper will discuss
the role of FDG-PET/CT in the pretreatment staging, restag-
ing, treatment monitoring, assessment of transformation,
and posttherapy surveillance of patients with aggressive non-
Hodgkin’s lymphoma of B-cell origin. The discussion of
the role of FDG-PET/CT in the management of Hodgkin’s
disease is beyond the scope of this paper.
2. Imaging Considerations in Lymphoma
The management of lymphoma depends on histologic
subtype, stage, and grade. HL and the more aggressive forms
of NHL share similar radiologic imaging patterns with the
near universal use of combined FDG-PET/CT for assessment
[6, 7]. Combined FDG-PET/CT is now considered the
most accurate tool for diagnosis, assessment of treatment2 ISRN Hematology
response, and prognosis in patients with aggressive NHL
[8]. There are a number of caveats that one must be
aware of when interpreting FDG-PET/CT in the setting
of lymphoma. Certain subtypes of B-cell lymphoma, par-
ticularly extranodal marginal zone lymphoma and periph-
eral T-cell lymphoma, display variable FDG uptake and
can also be sometimes diﬃcult to identify on contrast
enhanced CT (CECT) [9]. In these cases, a baseline FDG-
PET/CT is essential to facilitate meaningful interpretation
of posttreatment imaging in terms of treatment response.
A number of subtypes of lymphoma may be diﬃcult or
almost impossible to detect with FDG-PET/CT such as
primary CNS lymphoma, testicular lymphoma, and gastric
lymphoma.Thenormalbrainandtestesdemonstrateintense
FDG avidity and against this high background FDG activity,
primary CNS and testicular lymphoma may be very diﬃcult
to detect without adjusting the image intensity thresholds
[10]. Gastric lymphoma displays an extremely variable FDG
uptake that may be diﬃcult or impossible to diﬀerentiate
from normal physiologic FDG uptake in the gastric mucosa
[11]. Diﬀuse or heterogeneous bone marrow uptake of
radiotracer in a pretreatment scan should not immediately
suggest bone marrow involvement by lymphoma as this
pattern of uptake can be seen in reactive myeloid hyperplasia
[5, 12]. Focally increased FDG uptake can also be seen in
the musculoskeletal system due to trauma, muscle activity,
and degenerative change in synovial joints and also in brown
fat which has a higher basal metabolic rate than adjacent
tissues and may be mistaken for a lymphoma deposit.
However, brown fat has a characteristic distribution and
its detection is usually reasonably straightforward on FDG-
PET/CT [13]( Figure 1). If patients with lymphoma are
treated with granulocyte-colony stimulating factors, their
bone marrow may show a diﬀuse increase in FDG uptake.
It is very important to recognize the aforementioned pitfalls
to avoid false-positive interpretation of FDG-PET/CT scans
and hence potential overstaging of patients.
2.1. FDG-PET/CT Technique. There is a wide variance in
the protocols used to obtain FDG-PET/CT images with
variations in the use of intravenous contrast and the tube
current (and hence radiation dose) used in the CT compo-
nent of the study. In general, a patient who is undergoing
an FDG-PET/CT scan will have their blood glucose level
measured prior to the intravenous administration of FDG
and if the serum glucose concentration is too high (above
140mg/dL), a subcutaneous injection of rapid acting insulin
may be considered [14]. The patient is placed in a recumbent
position and instructed to limit movement as this will reduce
muscleactivityandpreventunwantedFDGuptakeinskeletal
muscle. An intravenous dose of FDG is administered (the
dose is dependent on the patient’s weight) and imaging
is performed 1-2 hours (usually 1 hour) after injection
as this allows a steady state of FDG uptake. Imaging is
performed using an FDG-PET/CT scanner which integrates
a multidetector CT scanner with a high-resolution PET
scanner, facilitating the acquisition of three-dimensional
images. Axial whole-body FDG-PET/CT images are acquired
from the vertex or skull base to the upper thigh [8].
The “whole-body” nature of the imaging technique makes
FDG-PET/CT ideal for evaluating systemic diseases such as
lymphoma.
2.2. Standardized Uptake Value (SUV). SUVs represent
reproducible estimates of tissue glucose metabolic activity
and can be used for semiquantitative analysis of ﬁndings
on FDG-PET/CT in patients with lymphoma [15]. This
is very useful in clinical practice as it allows accurate
comparison of lesions on subsequent scans (i.e., to guide
response to treatment) and can be used to evaluate the
degree of residual metabolic activity in a treated mass.
This helps physicians make clinical decisions regarding
the use of salvage chemotherapy [16]. While the SUV is
semiquantitative, a number of studies have demonstrated
that visual assessment of treatment response in patients with
lymphoma is adequate for determining whether an FDG-
PET/CT scan is positive for disease [6, 7].
2.3. FDG-PET/CT versus CT. FDG-PET/CT is often not the
ﬁrst-line imaging modality in the assessment of a patient
withsuspectedlymphoma.CTiswidelyavailableand,inpart
due to ease of access and cost factors, it was the dominant
radiologic tool for the assessment of lymphoma over the past
three decades. Lymphoma displays homogenous attenuation
on CT with characteristic patterns of disease such as vessel
encasement and displacement (the so-called “sandwich
sign” [17]) and spread across existing anatomic structures
which indicates an aggressive, permeative disease process [8]
(Figure 2).
However, the fundamental limitation of CT in imaging
lymphoma is that recognition of nodal involvement by
disease is based solely on size criteria and the detection of
bone marrow and extranodal involvement is limited. FDG-
PET/CTincorporatesaCTcomponentinadditiontoaFDG-
PET scan, and it has been demonstrated to have a higher
sensitivity and speciﬁcity for the detection of nodal and
extranodal sites of disease when compared to CT alone,
thus improving baseline staging [8, 18–20]. It has long
been recognized that CT is limited in its ability to assess
the response of lymphoma to treatment as CT cannot
diﬀerentiate between viable tumor and necrosis or ﬁbrosis
in patients presenting with persistent masses posttreatment
[21].ThesensitivityandspeciﬁcityofFDG-PET/CThasbeen
showntobesuperiortothatofCTaloneintheposttreatment
assessment of lymphoma due to the addition of information
regarding the metabolic activity of residual masses (RMs)
detected on CT [8, 20].
2.4. FDG-PET/CT versus Gallium-67 Citrate Scintigraphy.
The development and clinical utilization of the ﬁrst molec-
ular imaging agent for lymphoma assessment, namely,
Gallium-67 citrate (67Ga), greatly improved the accuracy of
treatment response assessment in patients with lymphoma
[22–24]. 67Ga scanning is based on the accumulation of the
isotope into viable lymphoma cells by binding to transferrin
receptors [25]. It has been demonstrated that there is a
signiﬁcant diﬀerence in progression-free survival between
patients with treated lymphoma that have a positive orISRN Hematology 3
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Figure 1: Coronal PET maximum intensity projection (MIP) image (a) displaying foci of increased radiotracer uptake bilaterally in the neck
in a patient with treated DLBSL. The corresponding coronal CT (b) and fused FDG-PET/CT (c) demonstrate no abnormality and the areas
with increased FDG uptake correspond to regions of fat density (arrows). This is the characteristic appearance of hypermetabolic brown fat
on FDG-PET/CT.
(a) (b) (c)
Figure 2: Axial (a) and coronal (b) contrast enhanced CT of the abdomen in a patient with chronic lymphocytic leukemia displaying
encasement of vessels such as the left renal vein (white arrow) and right renal artery (black arrow) by lymph nodes masses, the so-called
“sandwich sign.” Axial contrast enhanced CT (c) of the abdomen at a lower level in the same patient displaying elevation of the abdominal
aorta oﬀ the vertebral column (white arrow) which is a characteristic feature of lymphoma and helps to diﬀerentiate lymphoma from other
retroperitoneal masses, such as retroperitoneal ﬁbrosis. Note the encasement of the superior mesenteric artery (SMA) by the lymph node
mass and increased separation of the SMA from the aorta (black arrow).
negative 67Ga scan; however, the positive and negative
predictive values of 67Ga imaging are suboptimal [22, 23].
There are a number of technical and clinical factors that
havelimitedtheuseandacceptanceof 67Gaimaging,namely,
its low spatial resolution, low sensitivity and speciﬁcity,
its limited use for imaging intra-abdominal disease (due
to physiologic bowel uptake), and the time involved in
performing the scan, which can take up to a week after 67Ga
injection [25, 26]. 67Ga imaging has been largely replaced
by FDG-PET, which is a radiolabelled isomer of glucose
and is hence a very sensitive marker of glucose metabolism
and metabolic activity [27]. FDG-PET is superior to 67Ga
scintigraphy in terms of sensitivity for the detection of and
speciﬁcity for malignant lymphoma [27–30]. The use of
FDG-PET/CT tends to upstage patients due to the detection
of additional sites of lymphomatous involvement such as
the liver, spleen, and lung which can result in a change of
treatment strategy [30–32].
3. FDG-PET/CTfor Primary Stagingof
Aggressive B-Cell Lymphoma
FDG-PET/CT has been demonstrated in multiple studies to
be very sensitive for the detection of nodal and extranodal
lymphoma at initial staging of patients prior to commence-
ment of treatment [33–40]. In general, indolent FL is asso-
ciated with low-grade FDG uptake, whereas more intense
FDG accumulation is seen in more aggressive lymphomas,
such as DLBCL [41]. In comparison to CT alone, FDG-
PET/CT detects additional foci of FDG uptake, presumed to
be lymphomatous deposits, in subcentimeter lymph nodes
and particularly in extranodal sites such as the liver, spleen,
bone marrow, and muscle in patients with DLBCL with an
impact on disease stage (usually upstaging) in approximately
15–20% of patients and with an inﬂuence on clinical
management in approximately 5–15% [33–37, 42]. FDG-
PET/CT is more accurate for staging than both FDG-PET4 ISRN Hematology
(a) (b) (c)
Figure 3: Coronal CT (a) demonstrating left cervical and right paratracheal lymphadenopathy (white arrows) and mild splenomegaly
(white arrowhead) consistent with high-grade follicular lymphoma. Corresponding coronal fused FDG-PET/CT (b) demonstrates increased
radiotracer uptake in the pathologically enlarged left cervical and right paratracheal lymphadenopathy (white arrows) and spleen (white
arrowhead), but also abnormal FDG accumulation in right cervical and left external iliac lymph nodes (white arrows) that appeared normal
by size criteria on the corresponding CT scan. Coronal PET MIP (c) in the same patient demonstrating widespread increased radiotracer
uptake throughout the neck, thorax, abdomen, and proximal humeri and femora bilaterally; the widespread bone marrow involvement was
not apparent on CT.
and CT alone, with equal sensitivity and better speciﬁcity
[30]. Pretreatment FDG-PET/CT imaging acts as a baseline
study to facilitate comparison to posttreatment scans to
assess response to treatment and evaluate RMs for metabolic
activity [6, 7]. FDG-PET/CT has been demonstrated to
be eﬀective in the detection of focal or multifocal bone
marrow inﬁltration in patients with a negative iliac crest
bonemarrowbiopsy(BMB)[43].However,itisimportantto
stress that FDG-PET/CT alone is not completely reliable in
detecting limited bone marrow involvement by lymphoma,
and, hence, it cannot entirely replace BMB in the initial
diagnosis of lymphomas of any type as a negative FDG-
PET/CT scan cannot deﬁnitively outrule involvement of the
bone marrow by lymphoma [44]( Figure 3).
Combined FDG-PET/CT imaging represents a func-
tional and anatomical approach to lymphoma assessment
which exploits the strengths of both modalities while at the
same time minimizing the shortcomings of each individual
modality. A number of studies have demonstrated that a
staging FDG-PET/CT scan provides diagnostic information
that is at least equal but likely superior to that which is
provided by a separate FDG-PET and intravenous contrast
enhanced CT (CECT) scan [7, 12]. FDG-PET provides the
functional information lacking on CT images that may
represent the only indication of disease (e.g., abnormal
FDG uptake in a normal-sized lymph node on CT). CT
provides superior anatomic detail and spatial resolution that
is lacking in FDG-PET which enables better localization of
FDG uptake and, importantly, may identify false-negative
FDG-PET ﬁndings due to the limited spatial resolution of
PET scanners or lack of FDG avidity of some subtypes of
lymphoma. The anatomic correlation of FDG uptake that
is aﬀorded by FDG-PET/CT is also very useful in reducing
the rate of false-positive ﬁndings due to physiologic FDG
uptake in, for example, muscle or brown fat [45]. There
is debate in the published literature regarding the beneﬁts
of using intravenous contrast during the CT portion of a
FDG-PET/CT scan. Some authors suggest that the use of
intravenous contrast reduces the number of indeterminate
ﬁndings on FDG-PET/CT and results in the detection
of a higher number of extranodal sites compared with
FDG-PET/CT performed without intravenous contrast [46].
However, a number of studies suggest that an FDG-PET/CT
scan performed without intravenous contrast and using a
low radiation dose CT technique is an acceptable alternative
to separate CECT and FDG-PET scans even when the known
limitations of the unenhanced CT in the evaluation of the
liver and spleen are taken into account [19, 47]. It is the
opinionoftheauthorsthat,forinitialstagingofpatientswith
lymphoma,anFDG-PET/CTscanusingastandardradiation
dose CT protocol and intravenous contrast is the optimal
choice as a single imaging modality.
4. FDG-PET/CT for Restaging of
Aggressive B-Cell Lymphoma
Restaging of lymphoma refers to imaging patients after
completion of treatment or to determine the degree of
known or suspected disease recurrence. This is distinct from
treatment monitoring in which a patient is reimaged during
treatment, usually after two to three cycles of a six-to-eight-
cyclechemotherapyregimen[12].Theimagingevaluationof
treatment response was previously limited to the assessment
of changes in lymph node size with CT. This led to
a common diagnostic dilemma regarding residual lymph
node masses as to whether they represented posttreatment
ﬁbrosis or residual, viable malignancy. The presence of
residual active disease is associated with early relapse and
poor clinical outcome and usually necessitates further, more
aggressive treatment [48, 49]. FDG-PET/CT is very useful
in the restaging of lymphoma posttreatment as it can
reliably discriminate between benign ﬁbrosis (low or absent
FDG uptake) and residual viable lymphoma (elevated FDG
uptake) [5]. The International Harmonization Project (IHP)ISRN Hematology 5
[6, 7] in lymphoma made a number of recommendations
intended to reduce the rate of false-positive FDG-PET scan
interpretation after completion of treatment.
(1) FDG-PET/CT should not be performed for at least
3 weeks after chemotherapy and 8–12 weeks after
radiotherapy to minimize confounding FDG uptake
secondary to posttreatment inﬂammation.
(2) RMs ≥2cminmaximumtransversediametershould
only be considered positive for residual disease on
FDG-PET if their FDG avidity visually exceeds that
of the mediastinal blood pool structures.
(3) RMswithamaximumtransversediameter<2cmare
considered FDG-PET positive if their FDG uptake is
higher than the surrounding background tissue.
(4) In the liver and spleen, focal lesions with FDG
avidity greater than in surrounding liver or spleen
parenchyma are considered positive for viable lym-
phoma.
(5) Single or multiple foci of distinctly elevated FDG
uptake in the bone marrow is positive for residual
disease.
(6) Visual assessment alone is adequate for determining
whether FDG-PET scans are positive or negative at
the conclusion of treatment and SUV measurement
is not necessary.
The use of FDG-PET/CT in restaging lymphoma is
supported by a large body of evidence that shows that FDG-
PET/CT has a high negative predictive value (NPV) that
exceeds 80% in practically all reported studies for aggressive
NHL, with the reported 10–20% false-negative rate mainly
attributed to the inability of FDG-PET/CT to detect micro-
scopic disease which results in future relapse [6, 7, 12, 50–
53]( Figure 4). However, the positive predictive value (PPV)
of FDG-PET/CT is reported in the moderate range of 70–
80% which is signiﬁcantly lower and more variable than
its NPV and is due to the recognized false-positive rate
on FDG-PET due to persistent metabolic activity in RMs
posttreatment that often represents inﬂammatory change
rather than residual disease. The PPV of FDG-PET/CT is
substantially higher than that of CT alone which has a
reported PPV in the range of 40–50% in posttreatment
aggressive NHL leading to a considerably higher accuracy
of FDG-PET/CT for response assessment when compared to
CT alone [6, 7, 12, 50–53]. The signiﬁcantly higher accuracy
of FDG-PET/CT for response assessment when compared
to CT alone justiﬁes the increased cost associated with dual
modality imaging when compared to CT or PET alone [54,
55].
5. FDG-PET/CTfor Interim
Treatment Monitoring
The use of FDG-PET/CT for treatment monitoring is based
ontheassumptionthatinterimimaging,typicallyperformed
after two to three cycles of chemotherapy, provides accurate
prediction of response to current treatment and ultimate
patient outcome [30, 56]. The application of FDG-PET/CT
in interim treatment monitoring of lymphoma has been
highly successful in Hodgkin’s disease [57, 58]. However, the
beneﬁts of FDG-PET/CT in the management of aggressive
NHL are less clear cut with conﬂicting reports in the
literature regarding the usefulness of interim FDG-PET/CT
in predicting treatment response and patient outcome with
most reports recommending further prospective studies to
ascertain the role of FDG-PET/CT in this respect [59–61].
There are a number of reported studies in the literature that
support this premise, particularly with regard to the high
NPV of interim FDG-PET/CT in patients with aggressive
NHL [62–66]. It is interesting to note that the PPV and,
hence, accuracy of interim FDG-PET scans that are visually
interpreted (i.e., without the use of semiquantitative SUV)
appeartodependonthe“strictness”ofcriteriausedtodeﬁne
a scan as positive with a number of studies demonstrating
that a more “liberal” interpretation of FDG-PET ﬁndings at
the site of RMs on interim FDG-PET results in higher PPV
and accuracy with no compromise in NPV [66–68]. This
“liberal” visual interpretation involves considering an FDG-
PET scan as negative if it displays only minimal FDG uptake
that is similar or only slightly greater in intensity than FDG
uptake in normal liver [66–68]. If these “liberal” criteria for
deﬁning FDG-PET negativity are used, interim FDG-PET
was found to be at least as accurate for predicting patient
outcome as end of treatment FDG-PET interpreted using
“strict” criteria that does not allow any residual FDG uptake
in RMs [68].
Thus, the prognostic power of an interim FDG-PET/CT
scan is signiﬁcant with a number of studies indicating that a
negative interim FDG-PET scan in patients with aggressive
NHL confers an excellent prognosis while a positive study
identiﬁes patients who are likely to experience early relapse
and in whom a change in treatment regimen may be
beneﬁcial [51, 65, 66]. It must be stressed, however, that
interim FDG-PET/CT has a relatively limited PPV when
compared to its NPV due to the occurrence of false-positive
results due to posttreatment inﬂammation in RMs. Thus,
caution should be exercised when considering changing
a patient’s treatment regimen based on the ﬁndings of
FDG-PET/CT imaging alone and it is reasonable to biopsy
this patient group if such a change in treatment is being
contemplated [69]. Interim FDG-PET/CT scans appear to
be very useful in providing a basis for risk-adjusted or
“personalized” therapy, whereby the results of interim FDG-
PET/CT scans will identify patients who have responded well
to initial treatment (i.e., they have a negative interim scan)
and therefore will be suitable for a more limited treatment
regimen (i.e., reduced numbers of chemotherapy cycles
with less treatment-related toxicity) without compromising
treatment eﬃcacy or those patients in whom response to
initial treatment was poor (i.e., they have a positive interim
scan) and therefore an early change of treatment regimen
may improve patient outcome [69]( Figure 5).6 ISRN Hematology
(a) (b)
Figure 4: Coronal fused FDG-PET/CT image (a) demonstrating increased radiotracer uptake in multiple intra-abdominal lymph node
masses in a patient with DLBCL (white arrows). Note how a large soft tissue mass displaces the small bowel and the mesenteric vessels (white
arrowhead). Coronal fused FDG-PET/CT image (b) in the same patient demonstrating complete resolution of the previously described
soft tissue masses. The observed residual FDG avidity is within bowel and is normal. This FDG-PET/CT conﬁrms complete response to
treatment.
(a) (b)
Figure 5: Coronal fused FDG-PET/CT image (a) of a patient with nodular sclerosis type Hodgkin’s lymphoma prechemotherapy
demonstrating an FDG-avid lymph node mass in the superior mediastinum (white arrowhead) and hypermetabolic bilateral axillary
lymphadenopathy (white arrows). Interim staging coronal fused FDG-PET/CT image (b) in the same patient after 3 cycles of chemotherapy
demonstrating a signiﬁcant interval decrease in both the degree of FDG uptake and the size of the lymph node mass in the superior
mediastinum (white arrow) with resolution of the axillary lymphadenopathy.
6. FDG-PET/CTfor Posttreatment Surveillance
The use of FDG-PET/CT for posttreatment surveillance
in patients with aggressive NHL is performed following
completion of treatment and in the absence of clinical,
biochemical, or radiologic evidence of disease recurrence
(i.e., a complete response (CR) to treatment) with the
aim of early detection of disease relapse and hence earlier
treatment to improve patient outcome [25]. A recent study
reported positive results with the use of surveillance FDG-
PET scanning in 421 lymphoma patients (160 HL, 183
aggressive NHL, and 78 indolent NHL) who were imaged
at 6-month intervals for 2 years and then yearly thereafter
following initial CR. This study demonstrated that the
detection rate of proven relapses was higher with FDG-
PET compared with CT alone or clinical assessment in
aggressive NHL (31% versus 25% and 22%, resp.) and
indolent NHL (60% versus 49% and 38%, resp.) [70]. The
same study identiﬁed 36 patients with borderline positive
FDG-PET ﬁndings who subsequently underwent biopsy
that demonstrated lymphoma relapse in 24 patients and
12 false-positive ﬁndings (nine lymph nodes displaying
reactive hyperplasia and three patients with sarcoid-like
granulomatosis) [70]. While this study is encouraging, it did
not determine whether surveillance FDG-PET scanning was
cost eﬀective and whether the results of surveillance imaging
improved clinical outcomes. A study by Petrausch et al. [71]
demonstrated that FDG-PET/CT detected recurrent DLBCL
after ﬁrst CR with a high PPV (85%); however, the authors
report that it should not be used routinely and only in
selected high-risk patients (such as patients >60 years of age
and patients <60 years of age with clinical signs of relapse)
to reduce radiation dose to patients in remission and costs.
FDG-PET/CT has failed to demonstrate a clear beneﬁt inISRN Hematology 7
posttreatment surveillance, and thus, until large prospective
trials address these issues, the use of FDG-PET/CT for
disease surveillance will remain controversial with some
authors suggesting that its use should be limited to a clinical
trial setting [69, 72]. If there is a low clinical suspicion
for recurrence of patients with treated initially FDG-avid
lymphomas, then FDG-PET/CT scan using a low radiation
dose CT protocol without intravenous contrast may be a
reasonable choice of a single lower-dose imaging modality
for follow-up assessment. The routine use of FDG-PET/CT
in disease surveillance is not yet supported by a suﬃcient
body of evidence to justify its cost and associated radiation
dose, and there are also some issues in relation to false-
positive FDG-PET/CT studies during disease surveillance
which could cause unwarranted patient distress and further
add to the cost of management.
7. FDG-PET/CTfor Assessment
of Transformation
The transformation of indolent lymphoma to a higher grade
of lymphoma can occur, most commonly with DLBCL, and
is associated with a very poor prognosis and is an indication
for aggressive, high-dose chemotherapy and postremission
stem cell transplantation [73, 74]. FDG-PET/CT is useful to
conﬁrm the clinical suspicion of transformation of an indo-
lent lymphoma to a more aggressive histology by identifying
sites of abnormally high FDG uptake (indolent lymphoma
normally has low-grade FDG uptake) and also guiding selec-
tion of an optimal biopsy site for pathologic conﬁrmation
of transformation [41, 73]. Due to the signiﬁcant overlap in
the degree of FDG uptake between indolent and aggressive
lymphomas, FDG-PET/CT cannot entirely replace biopsy in
the assessment of transformation of lymphoma but rather
may be a useful alternative when a biopsy is not practical due
to technical or clinical reasons [41, 75].
8. Conclusion
FDG-PET/CT is an established imaging modality that has
been proven to be of beneﬁt in the management of aggressive
B-cell NHL, such as DLBCL and advanced stage FL. The
combination of anatomic and functional imaging aﬀorded
by FDG-PET/CT has led to superior sensitivity and speci-
ﬁcity in the primary staging, restaging, and assessment of
response to treatment of hematological malignancies when
compared to FDG-PET and CT alone. The use of FDG-
PET/CT for posttreatment surveillance imaging remains
controversial, and further study is needed to ascertain
whetherthismodalityiscosteﬀectiveandappropriateforuse
in this setting.
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